Cor Vasa 2020, 62(6):625-628 | DOI: 10.33678/cor.2020.112

(Do we need another intravenous beta-blocker?)

Tomáš Janota
III. interní klinika, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze

Beta-blockers are useful in a number of clinical situations. However, the benefits of new short-acting drugs in critically ill patients are not well-known or fully appreciated. The following article is mainly devoted to the benefits of landiolol with a very short duration of action and extraordinary β1 selectivity in patients with tachycardia or tachyarrhythmias and concomitant heart failure to shock, aortic dissection, perioperative period, acute coronary syndromes, takotsubo syndrome, but also angiography.

Keywords: Intravenous beta-blockers, Heart failure, Shock

Received: October 28, 2020; Revised: October 28, 2020; Accepted: November 24, 2020; Published: December 11, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janota T. (Do we need another intravenous beta-blocker?). Cor Vasa. 2020;62(6):625-628. doi: 10.33678/cor.2020.112.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hindricks G, Potpara T, Dagres N, et al. The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020;00:1-125 ESC GUIDELINES. https://doi:10.1093/eurheartj/ehaa612 Go to original source... Go to PubMed...
    2. Gray RJ, Bateman TM, Czer LS, et al. Esmolol: a new ultrashort--acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias. J Am Coll Cardiol 1985;5:1451-1456. Go to original source... Go to PubMed...
    3. Rapibloc 300 mg powder for solution for infusion: summary of product characteristics. http://www.medicinesauthority.gov.mt/; 2017. Navštíveno 11. 2018.
    4. Syed YY. Landiolol: a review in tachyarrhythmias. Drugs 2018;78:377-388. Go to original source... Go to PubMed...
    5. Plosker GL. Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias. Drugs 2013;73:959-977. Go to original source... Go to PubMed...
    6. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J 2014;78:1997-2021. Go to original source... Go to PubMed...
    7. Kobayashi S, Susa T, Tanaka T, et al. Low-dose b-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. Circ J 2012;76:1646-1653. Go to original source... Go to PubMed...
    8. Nagai R, Kinugawa K, Inoue H, et al. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J 2013;77:908-916. Go to original source... Go to PubMed...
    9. Adachi T, Sato A, Baba M, et al. Novel use of the ultra- -short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure. Heart Vessels 2014;29:464-469. Go to original source... Go to PubMed...
    10. Yamashita T, Nakasu Y, Mizutani H, Sumitani K. A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey. J Cardiol 2019;74:418-425. Go to original source... Go to PubMed...
    11. Wada Y, Aiba T, Tsujita Y, et al. Practical applicability of landiolol, an ultra-short-acting β1-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction. J Arrhythm 2016;32:82-88. Go to original source... Go to PubMed...
    12. Kiuchi S, Aikawa H, Hisatake S, et al. Efficacy of intravenous administration of landiolol in patients with acute heart failure and supraventricular tachyarrhythmia. J Clin Med Res 2017;9:426-432. Go to original source... Go to PubMed...
    13. Leibovici L, Gafter-Gvili A, Paul M, et al. TREAT Study Group. Relative tachycardia in patients with sepsis: An independent risk factor for mortality. QJM 2007;100:629-634. Go to original source... Go to PubMed...
    14. Xinqiang L, Weiping H, Miaoyun W, et al. [Esmolol improves clinical outcome and tissue oxygen metabolism in patients with septic shock through controlling heart rate]. Zhoiighua Wei Zhong Bing Ji Jiu Yi Xue 2015;27:759-763.
    15. Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short--acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med 2015;4:251-257. Go to original source... Go to PubMed...
    16. Walkey AJ, Evans SR, Winter MR, et al. Practice patterns and outcomes of treatments for atrial fibrillation during sepsis: a propensity-matched cohort study. Chest 2016;149:74-83. Go to original source... Go to PubMed...
    17. Arita Y, Segawa T, Yamamoto S, Hasegawa S. Landiolol is effective for the treatment of tachycardia induced cardiogenic shock in patients during septic shock therapy. BMJ Case Rep 2017;2017:bcr2017222268. Published online 2017 Nov 1. doi: 10.1136/bcr-2017-222268 Go to original source... Go to PubMed...
    18. Bignami E, Guamieri M, Franco A, et al. Esmolol before cardioplegia and as cardioplegia adjuvant reduces cardiac troponin release after cardiac surgery. A randomized trial. Perfusion 2017;32:313-320. Go to original source... Go to PubMed...
    19. Mehlhorn U, Sauer H, Kuhn-Régnier F, et al. Myocardial beta-blockade as an alternative to cardioplegic arrest during coronary artery surgery. Cardiovasc Surg 1999;7:549-557. Go to original source... Go to PubMed...
    20. Zangrillo A, Turi S, Crescenzi G, et al. Esmolol reduces perioperative ischemia in cardiac surgery: A meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth 2009;23:625-632. Go to original source... Go to PubMed...
    21. Sezai A, Minami K, Nakai T, et al. Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: New evidence from the PASCAL trial. J Thorac Cardiovasc Surg 2011;141:1478-1487. Go to original source... Go to PubMed...
    22. Nishi H, Sakaguchi T. Miyagawa S, et al. Efficacy of landiolol hydrochloride for atrial fibrillation after open heart surgery. Heart Vessels 2013;28:490-496. Go to original source... Go to PubMed...
    23. Shibata SC, Uchiyama A, Ohta N, et al. Efficacy and safety of Landiolol compared to amiodarone for the management of postoperative atrial fibrillation in intensive care patients. J Cardiothorac Vase Anesth 2016;30:418-422. Go to original source... Go to PubMed...
    24. Sakai M, Jujo S, Kobayashi, et al. Use of low-dose β1-blocker for sinus tachycardia in patients with catecholamine support following cardiovascular surgery: a retrospective study. J Cardiothorac Surg 2019;14:145. Go to original source... Go to PubMed...
    25. Strayer RJ, Shearer PL, Hermann LK. Screening, evaluation, and early management of acute aortic dissection in the ED. Curr Cardiol Rev 2012;8:52-57. Go to original source... Go to PubMed...
    26. Saeki N, Taguchi S, Kawamoto M. Successful management of a patient with Marfan syndrome complicated with acute aortic dissection using landiolol during Cesarean section. J Anesth 2010;24:277-279. Go to original source... Go to PubMed...
    27. Kamata K, Morioka N, Nomura M, et al. [Short-acting beta 1-adrenergic blocker is useful for anesthetic management of Cesarean section in a patient with Marfan syndrome]. Masui 2004;53:298-301. Go to PubMed...
    28. Hoshi T, Sato A, Nishina H, et al. Acute hemodynamic effects of landiolol, an ultra-short-acting beta-blocker, in patients with acute coronary syndrome: Preliminary study. J Cardiol 2012; 60:252-256. Go to original source... Go to PubMed...
    29. Maurovich-Horvat P, Kârolyi M, Horvath T, et al. Esmolol is noninferior to metoprolol in achieving a target heart rate of 65 beats/min in patients referred to coronary CT angiography: A randomized controlled clinical trial. J Cardiovasc Comput Tomogr 2015;9:139-145. Go to original source... Go to PubMed...
    30. Hirano M, Yamashina A, Hara K, et al. Landiolol Hydrochloride Study Group. A multicenter, open-label study of an intravenous short-acting β1-adrenergic receptor antagonist landiolol hydrochloride for coronary computed tomography angiography by 16-slice multi-detector computed tomography in Japanese patients with suspected ischemic cardiac disease. Drugs R D 2014;14:185-194. Go to original source... Go to PubMed...
    31. Degertekin M, Gemici G, Kaya Z, et al. Safety and efficacy of patient preparation with intravenous esmolol before 64-slice computed tomography coronary angiography. Coron Artery Dis 2008;19:33-36. Go to original source... Go to PubMed...
    32. Kido T, Mochizuki T, Hirano M, et al. Radiation-Dose-Lowering Effects of Landiolol Hydrochloride in Coronary Angiography Using Computed Tomography (DELIGHT) - A Prospective Multicenter Study. Circ J 2016; 80:1225-1231. Go to original source... Go to PubMed...
    33. Sudjud RW, Tatang B. Boom CE, et al. Beta blocker in post cardiac surgery patients. Indian J Clin Anesth 2016;3:492-496.
    34. Nakahara T, Toyama T, Tsushima Y, et al. Coronary vasospasm CT angiography. J Cardiovasc Comput Tomogr 2014;8:328-330. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes